about
Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivoPatterns of transmitted HIV drug resistance in Europe vary by risk groupLow level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.Epigenetic analysis of HIV-1 proviral genomes from infected individuals: predominance of unmethylated CpG's.Multicenter quality assessment of PCR methods for detection of enteroviruses.Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and EncephalitisIncrease in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition.A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations.Computational methods for the design of effective therapies against drug resistant HIV strains.Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patientsHIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics.Limited cross-border infections in patients newly diagnosed with HIV in EuropeTenofovir resistance and resensitizationSingle-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay.Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.European guidelines on the clinical management of HIV-1 tropism testing.HTLV-1 associated myelopathy after renal transplantation.A reporter system for Epstein-Barr virus (EBV) lytic replication: anti-EBV activity of the broad anti-herpesviral drug artesunate.Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.Delayed seroconversion and rapid onset of lymphoproliferative disease after transmission of human T-cell lymphotropic virus type 1 from a multiorgan donor.Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.Differential effects of P-class versus other CpG oligodeoxynucleotide classes on the impaired innate immunity of plasmacytoid dendritic cells in HIV type 1 infection.Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.Transmission of drug-resistant HIV-1 is stabilizing in Europe.Elevated CD40 ligand silences α interferon production in an HIV-related immune reconstitution inflammatory syndrome.Impaired plasmacytoid dendritic cell innate immune responses in patients with herpes virus-associated acute retinal necrosis.Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate.Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge.The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 SubtypesOptimized protocol for detection of HIV-1 drug mutations in patients with low viral loadThe N-Terminus of the HIV-1 p6 Gag Protein Regulates Susceptibility to Degradation by IDENo evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individualImages in clinical medicine. Cowpox infectionSeroreversion in vertically HIV-1-infected children treated early and efficiently: rule or exception?HIV-1 seroreversion following antiretroviral therapy in an HIV-infected child initially presenting with acquired immunodeficiency syndromeInfluence of major HIV-1 protease inhibitor resistance mutations on CTL recognitionEarly mortality of brain cancer patients and its connection to cytomegalovirus reactivation during radiochemotherapy
P50
Q24535740-6A818EC9-A610-424B-B7A3-C679782CC399Q28537726-F8893D7B-43DB-4962-B9A7-9F34CA54B567Q33595278-B006EAA0-A92F-42B2-9091-4E72B5DEEB62Q33768729-84BBE834-9216-484D-A524-0642BA0B2E6BQ33960180-65BEB111-F911-4ADE-B374-AFAB32685B71Q33992691-AD879E37-C055-486B-9811-C0903110F5F2Q34469240-E9911874-E9AA-49BE-8012-A570B8D2329CQ35006676-CB651981-2A58-4ABB-9FB0-D4F0BBA2F476Q35168968-F38932FF-725A-4C5B-BB8A-DA2B374B3BCFQ36250187-805BE0C7-6002-49F8-B42E-42B1ABB2BA21Q36367759-75B4EB95-A85E-41B0-95BC-54DBD3D8C3B6Q36588672-5D80D916-E96C-4BAF-AD91-D6334B266310Q36766901-2879D36B-8596-409C-9C7A-0F666793A9F3Q36879987-8E4D7D8B-350E-4F86-94A5-ADB8E49258E4Q37156958-4284DF5A-85C5-4DFD-B840-8F0538D7C100Q37278724-158CC428-94C0-4B0A-AEEA-2610C18B0BAFQ37856554-824160BC-14CF-4FA6-B511-7870B1830F67Q39038763-70D066CB-FC5C-4DA3-8E07-ACCDEC51D184Q39577351-FC1E31EB-E1C3-4D83-AA2E-4C35AC37C3FCQ40396257-7D237A4E-846F-4CE1-B0AE-68EF8472F3F2Q42275863-64D1F68B-2115-4F46-8ED3-69CF792B4440Q42797684-732338BB-D983-4D63-A11F-484A0C15263FQ43500808-8DF65163-A3A7-4B83-8F0B-4443503679EFQ44309121-3DD6B3FA-A9DC-4978-8B26-A32AFE96F780Q44591236-FD60F473-93E9-4546-A2A0-32B606DEEDC2Q45198790-5910D01E-D63E-4AF2-8BB5-08F2BD32254DQ45400659-209F35DC-C0DD-456B-A135-5BBBE9A349F2Q45980742-D7DDAD8C-7A29-44FC-B5D8-E1D8208896D1Q46558862-A6F20049-C787-4303-8300-96D3536678C0Q50145794-363C3B0D-535C-4A62-978D-57C1A0F22F73Q56778335-2869C3DC-856B-4D98-B36A-FD47695C6881Q58323658-317AD464-3888-49A3-B0EB-A000DB4ABF83Q60959432-1439E333-39BC-4AE6-A963-74AE5E2B0C98Q78413159-C19762D0-14A0-4261-A253-FFBFD84A4AF0Q78853132-CD9FB59C-FE4E-4C45-9EA9-41429CBC0C8CQ82082534-6649535E-DF06-439B-AB49-966C88258FECQ82317883-E669D5A6-F65D-423D-BDD3-7FD0CB3402C0Q82603290-9E089AA9-3CBE-44C1-9C15-F95642A1CFE7Q89721958-A9608539-B302-4AF3-AF76-AC87A6129F15
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Klaus Korn
@ast
Klaus Korn
@en
Klaus Korn
@es
Klaus Korn
@nl
Klaus Korn
@sl
type
label
Klaus Korn
@ast
Klaus Korn
@en
Klaus Korn
@es
Klaus Korn
@nl
Klaus Korn
@sl
prefLabel
Klaus Korn
@ast
Klaus Korn
@en
Klaus Korn
@es
Klaus Korn
@nl
Klaus Korn
@sl
P106
P31
P496
0000-0003-1891-2107